We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Nanoparticles May Help Identify, Treat Tumors

By Biotechdaily staff writers
Posted on 08 May 2006
A new technique may in the near future help clinicians detect tumors during the initial stages of growth. More...
The technique allows nanoparticles to congregate inside cancerous tumors, creating masses with enough of a magnetic signal to be identifiable by magnetic resonance imaging (MRI) scanning.

The study, performed by engineers from the Massachusetts Institute of Technology (MIT; Boston, MA, USA), was published in the May 2006 issue of the journal Angewandte Chemie International Edition. The research, which is just going into animal trials, involves injecting nanoparticles (billionths of a meter in size) made of iron oxide into the body, where they flow through the bloodstream and enter tumors.

Solid tumors must form new blood vessels to grow in a process called angiogenisis. But because this growth is so fast in cancerous tumors, there are gaps in the endothelial cells that line the inside of the blood vessels. The nanoparticles can slide through these gaps to enter the tumors. Once inside the tumor, the nanoparticles can be prompted to group together by a process devised by the MIT engineers.

Specifically, specific enzymes called proteases inside the tumors cause the nanoparticles to "self-assemble,” or bind together. The resulting nanoparticle clusters are too large to get back out of the gaps. Furthermore, the clusters have a stronger magnetic signal than do individual nanoparticles, allowing detection by MRI.

"We inject nanoparticles that will self-assemble when they are exposed to proteases inside of invasive tumors,” said Sangeeta N. Bhatia, M.D., Ph.D., associate professor of the Harvard (Boston, MA, USA)-MIT Division of Health Sciences & Technology (HST) and Electrical Engineering and Computer Science (EECS). "When they assemble, they should get stuck inside the tumor and be more visible on an MRI. This might allow for noninvasive imaging of fast-growing cancer ‘hot spots' in tumors.”

The technique initially is being used to evaluate breast tumors. Dr. Bhatia added that it ultimately may be applied to many different types of cancers and to study the "triggers” that turn a benign mass in the body into a cancerous tumor. Nanoparticles also have the potential to deliver agents that could destroy cancer cells, replacing radiation or chemotherapy treatments that cause debilitating side effects such as hair loss or nausea.

The researchers hold a provisional patent on their work.



Related Links:
Massachusetts Institute of Technology

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Automatic Hematology Analyzer
CF9600
Automated Clinical Chemistry Analyzer
Envoy 500+
Immunofluorescence Analyzer
IFA System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Alzheimer’s pathology can start 15 to 20 years before symptoms, and validated tools that reach patients earlier help pave the way for earlier detection. (Image Credit: Adobe Stock)

Alzheimer’s Blood Test Becomes First FDA-Cleared Option for Adults as Young as 40

C2N Diagnostics’ PrecivityAD2 blood test was cleared by the U.S. Food and Drug Administration (FDA) on August 20, 2026, for adults as young as 40 who are experiencing signs of cognitive impairment, according... Read more

Pathology

view channel
Image: Adrenal gland tumor stained with hematoxylin and eosin (top) and CYP11B2 (bottom) (Photo courtesy of Christofer Juhlin)

Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism

Primary aldosteronism is a common but underdiagnosed cause of hypertension, in which excess aldosterone promotes salt retention and raises blood pressure. Identifying the dominant source of hormone overproduction... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.